P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

ABOUT CYTOGEN'S NEWS

streetblowjobs xndx

Date: 12 Dec 2007
Time: 09:32:57

Comments

http://www.streetblowjobs.com/?id=chikenn http://www.teamsquirt.com/?id=chikenn http://www.topshelfpussy.com/?id=chikenn http://www.trannysurprise.com/?id=chikenn http://www.tunaparty.com/?id=chikenn http://www.vipcrew.com/?id=chikenn http://www.welivetogether.com/?id=chikenn http://www.milfhunter.com/?id=chikenn

Date: 20 Jun 2001
Time: 08:18:06

Comments

Cytogen fans start asking about the impact of the agreement between Cryogen (CYTO) and its largest current shareholder, the State of Wisconsin Investment Board (SWIB), which ended in selling $8.19 million of common stock, or a total of 1,820,000 registered shares $4.50 per share to the State.

Like the press release said, for those investors whose main concern is balance sheets, this investment will satisfy them, as it provides funding to expand Cyto's prostate cancer franchise and its leadership position in charting protein-signaling pathways via our AxCell Biosciences subsidiary.

regarding Cyto, the firm has clearly stated that it was very pleased that the State of Wisconsin Investment Board continues to support its corporate strategy and recognizes the potential of its technology.

There is no doubt that being continuously supported by your State brings a comfortable feeling, which, in this case, must spread to Cyto's shareholders in and lessen the concerns of those who focus on the start-up finances more than their science and technology.

It is comforting also to see that the proceeds of the offering will be used primarily for advancing Ax Cell’s proprietary proteomics technology, marketing and sales initiatives for key oncology products, and development of the Company's prostate specific membrane antigen (PSMA) technology.

With regard to the State of Wisconsin, John Nelson, its Investment Director has stated that he is pleased to increase the State's position in Cytogen. He believes that the company has made significant progress in developing products for the oncology and proteomics markets.

We do not see any negatives in this agreement. Yet, the market is a market where each and every stock has friends and opponents. Of course those who benefit from falling stocks will interpret any news from any company, as bad, or less than expected and vice versa.

The only impact of this agreement is the fact that Cytogen has more money than before it. It can now move faster with its projects and plans.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName